Clobetasol Propionate

Clobetasol Propionate

SCHEMBL445257

CCC(=O)OC1(C(=O)CCl)C(C)CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NR3C1

The experimentally established mechanism targets of Clobetasol Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 known ✓ P04150 6/20 1.00
PGR P06401 6/20 1.00
CYP3A4 P08684 5/20 1.00
USP2 O75604 5/20 1.00
LMNA P02545 3/20 1.00
MAPT P10636 3/20 1.00
NR1I2 O75469 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
NPSR1 Q6W5P4 2/20 1.00
MLNR O43193 1/20 1.00
ABCB11 O95342 1/20 1.00
CYP3A5 P20815 1/20 1.00
PPARG P37231 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2C9 P11712 1/20 1.00
ADORA3 P0DMS8 3/20 0.84
DRD2 P14416 1/20 0.84
OPRD1 P41143 1/20 0.84
MEN1 O00255 1/20 0.75
KMT2A Q03164 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clobetasol Propionate SCHEMBL5577907 1.00 PGR (1.00) PGRNR3C1CYP3A4USP2LMNA
Clobetasol Propionate SCHEMBL17131797 1.00 PGR (1.00) PGRNR3C1CYP3A4USP2LMNA
Clobetasol Propionate SCHEMBL3997 1.00 PGR (1.00) PGRNR3C1CYP3A4USP2LMNA
Clobetasol Propionate SCHEMBL11052078 1.00 PGR (1.00) PGRNR3C1CYP3A4USP2LMNA
Clobetasol Propionate SCHEMBL11052079 1.00 PGR (1.00) PGRNR3C1CYP3A4USP2LMNA
Clobetasol Propionate SCHEMBL5577908 1.00 PGR (1.00) PGRNR3C1CYP3A4USP2LMNA
Clobetasol Propionate SCHEMBL10865006 1.00 PGR (1.00) PGRNR3C1CYP3A4USP2LMNA
Clobetasol Propionate SCHEMBL28118983 0.98 NR3C1 (0.95) PGRNR3C1CYP3A4USP2LMNA
Betamethasone Dipropionate SCHEMBL18301225 0.95 NR3C1 (0.93) PGRNR3C1CYP3A4USP2LMNA
SCHEMBL596943 0.94 NR3C1 (0.88) PGRNR3C1CYP3A4USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2073 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
EP-4301343-B1 PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME TLC BIOPHARMACEUTICALS INC (US) 2025-11-19 EP claimed
EP-4178579-B1 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AS GLUCOCORTICOID-SPARING AGENT METRIOPHARM AG (CH) 2025-02-12 EP claimed
EP-3773563-B1 PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2024-10-16 EP claimed
US-20240156839-A1 PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME TLC BIOPHARMACEUTICALS, INC. 2024-05-16 US claimed
EP-3728203-B1 DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS CHEMOCENTRYX INC (US) 2024-03-13 EP claimed
EP-4301343-A1 PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME TLC Biopharmaceuticals, Inc. (US) 2024-01-10 EP claimed
WO-2023183932-A2 MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) NEW YORK UNIVERSITY (US) 2023-09-28 WO claimed
US-20230241060-A1 GLUCOCORTICOID-SPARING AGENT METRIOPHARM AG (CH) 2023-08-03 US claimed
EP-4178579-A1 GLUCOCORTICOID-SPARING AGENT MetrioPharm AG (CH) 2023-05-17 EP claimed
EP-1758591-B1 INVERT EMULSION COMPOSITION CONTAINING CALCITRIOL AND CLOBETASOL 17-PROPIONATE, AND USES THEREOF IN COSMETICS AND DERMATOLOGY GALDERMA SA (CH) 2007-10-10 EP claimed
WO-2007012977-A2 STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF FOAMIX LTD (US) 2007-02-01 WO claimed
WO-2006131401-A2 CONTROLLED RELEASE OF A DRUG THROUGH SKIN ON THE BASIS OF A TOPICAL COMPOSITION COMPRISING A DRUG, A FILM-FORMING SILICONE AND AT LEAST ONE VOLATILE SOLVENT GALDERMA S.A. (CH) 2006-12-14 WO claimed
US-20060193789-A1 Surfacant, film forming agent, water, gas propellant; plant and animal extracts and oils; may include malathion FOAMIX LTD. (IL) 2006-08-31 US claimed
US-20060018937-A1 Steroid kit and foamable composition and uses thereof FOAMIX LTD. 2006-01-26 US claimed
EP-1496895-B1 USE OF CYCLOPAMINE IN THE TREATMENT OF PSORIASIS AND OTHER SKIN DISORDERS TAS SINAN (TR) 2005-11-16 EP claimed
EP-1087747-B1 FOAMING COMPOSITION FOR HAIR CARE GALDERMA SA (CH) 2005-11-09 EP claimed
EP-1205218-B1 Topical antipsoriaticum comprising urea, a corticoid and a desinfectant BENKERT EUGEN GEORG DR MED DEN (DE) 2004-03-31 EP claimed
EP-1205218-A1 Topical antipsoriaticum comprising urea, a corticoid and a desinfectant Benkert, Eugen Georg, Dr.med.dent. (DE) 2002-05-15 EP claimed
EP-0484529-B1 SKIN CREAM PREPARATION FOR EXTERNAL USE HISAMITSU PHARMACEUTICAL CO (JP) 1994-04-27 EP claimed